Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Magenta Therapeutics to Explore Strategic Alternatives

Casma Therapeutics Announces CEO Transition

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Tango Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TNG462; Provides Additional Business Updates